Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Leukemia & Lymphoma

Font Size

Gleevec Fights Rare Stomach Cancer

'Smart Bomb' Leukemia Drug Finding New Targets

WebMD Health News

Aug. 14, 2002 -- A promising new drug that zaps cancerous cells while leaving healthy ones unharmed is quickly finding new uses in treating previously untreatable types of cancer. New research shows the 'smart bomb' anticancer drug Gleevec can provide a valuable new treatment option for people with a rare and usually fatal form of stomach and intestinal cancer. Gleevec may also be useful in treating a rare bone marrow disease.

Gleevec was approved in May 2001 for treating a form of leukemia. It soon generated a lot of excitement among researchers for its ability to target cancer cells without damaging healthy ones.

Now, a new study shows the drug can treat a rare type of cancer that affects the stomach and intestines known as gastrointestinal stromal tumor (GIST).

Advanced forms of these tumors do not respond to conventional chemotherapy, radiation, or surgical treatments. Patients with advanced GIST usually survive less than two years after diagnosis.

But researchers found Gleevec was able to shrink tumors in more than half of the 147 patients who received the drug. Although no one had a complete remission, the tumor size was reduced by 50% to 96% in those who responded to the drug.

The findings appear in the Aug. 15 issue of TheNew England Journal of Medicine. Early results from this clinical trial prompted the FDA to approve Gleevec for treating GIST earlier this year.

The study found patients began to respond after an average of 13 weeks of daily treatment with the drug. And the benefits lasted more than 6 months.

Researchers say the drug works by blocking a substance that causes GIST to grow and spread.

Study author George D. Demetri, MD, of the Dana-Farber Cancer Institute and Harvard Cancer Center in Boston, and colleagues say targeting these growth-related mechanisms "is a promising treatment for advanced gastrointestinal stromal tumors, which resist traditional chemotherapy."

But the study authors caution that more research is needed to determine if using the drug actually prolongs life for people with this aggressive form of cancer.

In addition, they say new strategies are needed for increasing response to the drug and reducing resistance. Other studies of Gleevec have suggested that its effectiveness can wear off over time in some people as their bodies become resistant to the drug.

Today on WebMD

stem cells
What are they and why do we need them?
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
Vitamin D
New Treatments For Non-Hodgkins Lymphoma
Lifestyle Tips for Depression Slideshow
Pets Improve Your Health